Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. - Wikidata - wikimedia - TriplyDB

Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group.

Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group.

http://www.wikidata.org/entity/Q34925025

about

Nanoporous CREG-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries The representative porcine model for human cardiovascular disease Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement Stents Eluting 6-Mercaptopurine Reduce Neointima Formation and Inflammation while Enhancing Strut Coverage in Rabbits Preclinical study of a biodegradable polymer-based stent with abluminal sirolimus release.Effects of combined therapy with ezetimibe plus simvastatin after drug-eluting stent implantation in a porcine coronary restenosis model.Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy.Metabolic syndrome and coronary artery disease in Ossabaw compared with Yucatan swine.Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation.Endothelialization and in-stent restenosis on the surface of glycoprotein IIIa monoclonal antibody eluting stent.Quantitative analysis of high-resolution, contrast-enhanced, cone-beam CT for the detection of intracranial in-stent hyperplasia.Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates.Effect of anti-ApoA-I antibody-coating of stents on neointima formation in a rabbit balloon-injury model Drug-eluting stents: new era and new concerns.Early experiences and clinical implications of drug-eluting stents: part 1.Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease.Preclinical evaluation of a novel abluminal surface coated sirolimus eluting stent with biodegradable polymer matrix Technology Insight: an overview of research in drug-eluting stents.In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary Stents Sustained Efficacy and Arterial Drug Retention by a Fast Drug Eluting Cross-Linked Fatty Acid Coronary Stent Coating Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model Drug-induced thrombosis--experimental, clinical, and mechanistic considerations.Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries.Drug-eluting stent safety: findings from preclinical studies.Delivery site of perivascular endothelial cell matrices determines control of stenosis in a porcine femoral stent model.Translational research on novel drug-eluting stents in percutaneous coronary intervention.Drug-eluting coronary stents - focus on improved patient outcomes.Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary.Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent.Paving the way to a bioresorbable technology: Development of the absorb BRS program.Evaluation of biodegradable paclitaxel-eluting nanofibre-covered metal stents for the treatment of benign cardia stricture in an experimental model.Value of C-Arm Computed Tomography to Evaluate Stent Deployment During Femoro-Popliteal Revascularization.Lesion complexity determines arterial drug distribution after local drug delivery.Serial changes of neointimal tissue after everolimus-eluting stent implantation in porcine coronary artery: an optical coherence tomography analysis.Vascular Response to Experimental Stent Malapposition and Under-Expansion.A histopathological comparison of different definitions for quantifying in-stent neointimal tissue: implications for the validity of intracoronary ultrasound and optical coherence tomography measurements.Methotrexate eluting stents: to modify or cure?In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings.Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries.

P2860

Q27329486-07476DDF-9981-4966-9084-EDBDD068DBBB Q27692622-E47016F2-FAE9-4094-9E6A-2E9EA59290B8 Q28476506-935B24C6-4D2A-47B7-BE55-4054427761B1 Q28548292-EF775AC5-DCD6-4431-A9A7-D8E688566656 Q33733393-50762FD4-E8A1-41F4-B625-C24B775982FB Q33807236-D74657B2-1D9F-4AC4-9A7C-93298A5EB894 Q33992746-81ECDC98-6D0F-402C-B4C9-4C16398A98F0 Q34092599-28F67772-7E73-481E-B167-610640D8AD47 Q34109253-B937EA3A-1FF1-47C9-B25A-FC2029DFC582 Q34177967-720A4E60-A2D8-4299-AE4E-40A27A31C230 Q35048552-F0A9BB6A-8863-4E94-B312-5843E7A948EE Q35169065-51257B94-16BF-4EEC-A1CA-D79821F8FC5F Q35230921-80B7A862-BD13-4ADD-AC54-B26E923D0B07 Q35647727-EA8B3065-EC0F-434E-B756-D08AE3C23288 Q35651217-57655099-E5BB-4CA8-B156-E549EFA61FC2 Q35945466-9BA1136F-F606-453A-83FF-B739DD2A0D7D Q35953273-A0AE79FC-0F00-43B5-944A-D00DBBF83A8B Q36321778-E64096B3-7D2D-44A2-BC7D-4AB1AC722BF5 Q36470750-442C3452-2FE4-403A-95E7-1D05E88BE6CD Q36610213-EE797F6F-C3C4-484A-B242-0AA07D605A28 Q36619550-85CB5449-4BA9-43B7-8B4D-9A256DB15DD1 Q36693115-D53666F3-61F2-4641-9A7F-9D334DA39437 Q36762200-6CB97D7D-0605-4023-B15C-755840DBF014 Q37314517-8435D35A-A992-42B5-A0FC-E36CF29FAFB8 Q37329149-BCA69EF4-AEEA-4F31-BBB7-9320B6C7F667 Q37456910-0A081662-2973-41CC-BDF6-F57840738229 Q37971333-2BAF8884-38B9-458D-BFE9-136257CAE2D0 Q38037077-3CEB1BD9-A53E-4E2B-A92F-DA5392EDB2D7 Q38526979-86E6F181-F233-4C94-AB1A-EA9883132294 Q38961196-E104B1A0-FFE5-4C2D-84BD-CA9BC4F7BD83 Q38995000-9E3C64E9-EF60-475A-AD0B-693C15D9DC92 Q39229616-31289F5A-B148-4072-AF5E-0FF79AB0FCB3 Q40279276-06D0FFBD-38F8-4D97-9162-A9CFAFF6220E Q41415263-3B5C807C-61FC-48A4-8E34-7201A8DC17C2 Q41981596-2C160AFB-1282-471E-B786-591F8036F346 Q42574579-4F6483F6-E7FD-4BE6-AE7C-714219A39E61 Q42870553-AFA5F613-04C8-439F-A247-92F5C4A6F637 Q43013968-5F41F6FF-170B-47A2-93DF-EE3BBF59A017 Q43127564-4572F67B-3140-43FA-86DE-842698AAB5BD Q43237853-FA991A1E-E521-4281-AE45-28B9C70EAF28

P2860

Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group.

http://www.wikidata.org/entity/Q34925025

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Drug-eluting stents in preclin ...... uation from a consensus group.

@ast

Drug-eluting stents in preclin ...... uation from a consensus group.

@en

Drug-eluting stents in preclin ...... uation from a consensus group.

@nl

type

label

Drug-eluting stents in preclin ...... uation from a consensus group.

@ast

Drug-eluting stents in preclin ...... uation from a consensus group.

@en

Drug-eluting stents in preclin ...... uation from a consensus group.

@nl

prefLabel

Drug-eluting stents in preclin ...... uation from a consensus group.

@ast

Drug-eluting stents in preclin ...... uation from a consensus group.

@en

Drug-eluting stents in preclin ...... uation from a consensus group.

@nl

P1433

Q34925025-99AB9EF0-33F1-4AE7-A676-51976B957EE3

P1476

Q34925025-89CED800-7281-423F-B138-936E92C2E68D

P2093

Q34925025-11BB0CA9-D635-47CF-B5A0-E851B3B6887A

Q34925025-31EE3B38-E603-4252-8BED-EA19016FA2C5

Q34925025-34029BF3-1BF3-4F10-BB33-48595EB3F7C1

Q34925025-3D79EA4B-824F-4900-A8FD-681400C144F6

Q34925025-650DA714-1B20-4999-8498-F8F3E41EF04A

Q34925025-6A05AB10-6439-4C9D-96AA-66950BDE476A

Q34925025-82BB07F5-26CC-4903-AF49-52E69C45F994

Q34925025-8D8B8E6C-2526-445B-9BAE-56935C49D379

Q34925025-9932F582-E90E-40D8-B8EE-A67198B8AF6A

Q34925025-A0696AB4-BA4D-4D62-9981-2138CAFB8518

P304

Q34925025-9440C853-3761-4644-9E9A-2D641E8D97BD

P31

Q34925025-EF2D7778-BD18-4407-8310-5934462F39C6

P356

Q34925025-04C446EC-CC0A-4824-A9A3-83AF7C97276A

P407

Q34925025-DCFB26F2-FED9-4CAE-B721-2261199C5BF2

P433

Q34925025-1F41AC4E-FD7D-4A54-A295-D6CF8BB9AA48

P478

Q34925025-B8C33588-CA89-43E1-89DA-FC948969231C

P577

Q34925025-AC3F863F-1BF7-4EF7-99E0-38252C5732B3

P698

Q34925025-4FDF11FF-15C4-4359-B466-7019D5EE6C52

P356

01.CIR.0000033485.20594.6F

P1433

P1476

Drug-eluting stents in preclin ...... uation from a consensus group.

@en

P2093

Andrew Carter

http://www.w3.org/2001/XMLSchema#string

Bram D Zuckerman

http://www.w3.org/2001/XMLSchema#string

Campbell Rogers

http://www.w3.org/2001/XMLSchema#string

Consensus Committee

http://www.w3.org/2001/XMLSchema#string

Donald N Jensen

http://www.w3.org/2001/XMLSchema#string

Elazer R Edelman

http://www.w3.org/2001/XMLSchema#string

Judah Weinberger

http://www.w3.org/2001/XMLSchema#string

Keith A Robinson

http://www.w3.org/2001/XMLSchema#string

Nicolas Chronos

http://www.w3.org/2001/XMLSchema#string

Renu Virmani

http://www.w3.org/2001/XMLSchema#string

P304

1867-1873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.0000033485.20594.6F

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12356643

http://www.w3.org/2001/XMLSchema#string